OBJECTIVE： To observe clinical efficacy and safety of Xuebijing injection combined with octreotide and ulinastatin in the treatment of acute severe pancreatitis. METHODS： A total of 150 patients with acute severe pancreatitis admitted to emergency department of our hospital during Jan. 2012-Jan. 2016 were divided into control group， drug control group and observation group according to therapy method， with 50 cases in each group. All patients were treated with fasting， gastrointestinal decompression time， antibiotics， blood purification and other conventional treatment. Control group additionally received Cctreotide acetate injection 0.1 mg intravenously， tid， on the basis of conventional treatment. Drug control group additionally received Ulinastatin for injection 100 000 U added into 10％ Glucose injection 250 mL， ivgtt， bid， on the basis of control group. Observation group additionally received Xuebijing injection 100 mL added into 10％ Glucose injection 100 mL， ivgtt， bid， on the basis of drug control group. Three groups were treated for 10 days. The clinical indexes as fotal response rates， gastrointestinal decompression time， abdominal pain relief time， length of stay were observed in 3 groups. Related serum indexes （AMY， WBC， IL-6， CRP， TNF-α）  before and after treatment and the occurrence of compliance during treatment were compared among 3 groups. RESULTS： The total response rate of observation group was 90.0％， which was significantly higher than 72.0％ of drug control group and 52.0％ of control group， with statistical significance （P＜0.05）. The gastrointestinal decompression time， abdominal pain relief time and length of stay in observation group were significantly shorter than drug control group and control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the serum levels of AMY， WBC， IL-6， CRP or TNF-α among 3 groups （P＞0.05）. After treatment， above serum indexes of 3 groups were decreased significantly， and observation group was significantly lower than the drug control group and control group， with statistical significance （P＜0.05）. The incidence of ARDS， shock and acute renal failure in observation group were significantly lower than drug control group and control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of sepsis， abdominal abscess or MODS among 3 groups （P＞0.05）. CONCLUSIONS： Xuebijing injection combined with octreotide and ulinastatin show significant therapeutic efficacy for acute severe pancreatitis， can effectively control inflammation progress， improve clinical symptoms and promote disease recovery with good safety.